Trastuzumab Deruxtecan in HER2+ Gastric Cancer: Insights From DESTINY-Gastric02

Experts discuss the factors supporting the choice of trastuzumab deruxtecan following disease progression and its mechanism of action in addressing resistance to prior HER2-targeted therapy and provide insights on the updated analysis from the DESTINY-Gastric02 Trial.

Seg09_Insights

Video Player is loading.

Play Video

Play

Mute

Current Time 0:00

/

Duration 0:00

Loaded: 0%

0:00

Stream Type LIVE

Seek to live, currently behind liveLIVE

Remaining Time -0:00

 

1x

Playback Rate

Chapters

• Chapters

Descriptions

• descriptions off, selected

Captions

• captions settings, opens captions settings dialog
• captions off, selected

Audio Track

Fullscreen

This is a modal window.

Beginning of dialog window. Escape will cancel and close the window.

Text

ColorWhiteBlackRedGreenBlueYellowMagentaCyanTransparencyOpaqueSemi-Transparent

Background

ColorBlackWhiteRedGreenBlueYellowMagentaCyanTransparencyOpaqueSemi-TransparentTransparent

Window

ColorBlackWhiteRedGreenBlueYellowMagentaCyanTransparencyTransparentSemi-TransparentOpaque

Font Size

50%75%100%125%150%175%200%300%400%

Text Edge Style

NoneRaisedDepressedUniformDropshadow

Font Family

Proportional Sans-SerifMonospace Sans-SerifProportional SerifMonospace SerifCasualScriptSmall Caps

Reset restore all settings to the default valuesDone

Close Modal Dialog

End of dialog window.

Close Modal Dialog

This is a modal window. This modal can be closed by pressing the Escape key or activating the close button.

EP: 1.Robert’s Journey With HER2  Upper GI Cancer

EP: 2.Frontline Treatment and Molecular Testing in Upper GI Cancer: Precision-Guided Therapy

EP: 3.Reflex Testing in Upper GI Cancer: Optimizing Molecular Insights for Timely Treatment

EP: 4.The Role of Biomarkers for Immunotherapy Selection in Upper GI Cancer

EP: 5.Reassessing Biomarkers: Guiding Second-Line Therapy in Upper GI Cancer

EP: 6.Navigating Prognosis and Treatment Goals in Upper GI Cancer: A Patient- and Family-Centered Approach

EP: 7.Megan’s Journey With HER2+ Upper GI Cancer

EP: 8.Understanding PD-L1 CPS: Impact on Treatment Decisions in HER2+ Gastric Cancer

Now Viewing

EP: 9.Trastuzumab Deruxtecan in HER2+ Gastric Cancer: Insights From DESTINY-Gastric02

EP: 10.Biomarkers and Clinical Features Guiding HER2-Directed Therapy in Upper GI Cancer

Video content above is prompted by the following:

• What factors supported the choice of trastuzumab deruxtecan following disease progression, and how does its mechanism of action address resistance to prior HER2-targeted therapy?
• Please comment on updated analysis from the DESTINY-Gastric02 Trial.

Recent Videos

Second-Line Treatment for Gastric Adenocarcinoma

Advanced Metastatic Gastric Adenocarcinoma: Treatment Approaches

Gastric Adenocarcinoma: Current Treatment Landscape

Adjuvant Nivolumab in Gastric Cancers & CheckMate 8HW

Esophageal/Gastric Adenocarcinoma Standard of Care

BESPOKE: Study Design, Efficacy End Points and Methods

The Role of ctDNA in CRC

CAR T in High-Risk DLBCL: Making the Right Choice in Aggressive Disease

PSMA PET Imaging Agents: Image Quality and Diagnostic Performance

KEYMAKER-U03: Lenvatinib Plus Belzutifan Emerges as a Promising Option in Advanced RCC and New Directions From ASCO GU 2025